Bronchial Artery Chemoembolization (BACE) Combination Therapy for Advanced NSCLC

Official record

Identifier

NCT07738367

Recruiting locations

country

China

Interventions studied

Bronchial Arterial Chemoembolization (BACE)Systemic anti-tumor combination medications

Lead sponsor

Fujian Cancer Hospital

Target enrolment

20 participants

Study type

INTERVENTIONAL

Phase

Phase 2

Status

Enrolling by invitation

First posted

Jul 31, 2026

Last updated on the registry

Jul 31, 2026

Age

18 Years – 75 Years

Sex

ALL

Study contact

No public contact is listed on the official record.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

1. Age between 18 and 75 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2.
2. Histopathologically confirmed advanced non-small cell lung cancer (NSCLC), with at least one measurable target lesion defined by RECIST Version 1.1.
3. Two eligible patient subgroups:

   Patients with negative driver gene alterations: experienced disease progression or intolerable toxicity after platinum-based doublet chemotherapy combined with PD-1/PD-L1 immune checkpoint inhibitors; Patients with positive driver gene mutations (e.g., EGFR, ALK): experienced disease progression or unacceptable adverse reactions after corresponding targeted therapy plus at least one line of systemic chemotherapy.
4. Target lung lesions are suitable for bronchial arterial chemoembolization (BACE), as assessed by interventional radiology specialists.
5. Adequate function of major vital organs.
6. Able to provide written informed consent prior to any study-related procedures.

Exclusion Criteria:

1. Histopathological confirmation of mixed small cell lung cancer components.
2. Active bleeding or coagulation disorders.
3. Severe hypersensitivity to contrast media, chemotherapeutic agents, or combined study medications.
4. Extensive and rapidly progressive intra-pulmonary or extra-pulmonary metastatic lesions.
5. Angiography during the procedure shows that superselective catheterization cannot completely avoid hazardous blood vessels such as spinal arteries.
6. Severe pre-existing hepatic, renal, cardiac, or pulmonary dysfunction.
7. Estimated survival time less than 3 months.

Indexed under

Lung Cancer